ARTICLE | Clinical News
Sodium oxybate: Development discontinued
May 9, 2011 7:00 AM UTC
Jazz disclosed in its 1Q11 financial results that it will not conduct the additional trials of sodium oxybate that FDA requested in its October 2010 complete response letter for the fibromyalgia candi...